Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
Kneller, D.W., Li, H., Phillips, G., Weiss, K.L., Zhang, Q., Arnould, M.A., Jonsson, C.B., Surendranathan, S., Parvathareddy, J., Blakeley, M.P., Coates, L., Louis, J.M., Bonnesen, P.V., Kovalevsky, A.(2022) Nat Commun 13: 2268
- PubMed: 35477935 
- DOI: 10.1038/s41467-022-29915-z
- Primary Citation of Related Structures:  
7SI9, 7TDU, 7TEH, 7TFR - PubMed Abstract: 
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19 vaccines, and small-molecule antivirals can provide an important therapeutic treatment option. The viral main protease (M pro ) is critical for virus replication and thus is considered an attractive drug target ...